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found infiltration of valves by inflammatory cells to be 
absent or minimal. Although in Mitchell's study ho- 
mograft valves were examined at many postoperative 
intervals, valves that were removed 9 days to 2 months 
after implantation were not studied because the speci- 
mens were unavailable. Furthermore, the valves that were 
cxplanted at 2 to 4 months (n = 3) did demonstrate a 
prominent inflammatory infiltrate, including neutrophils, 
macrophages, and T-lymphocytes. However, these valves 
had failed because of infective endocarditis; therefore, 
even if there was a component of the infiltrate that may 
have been related to a rejection process, this would have 
been impossible to prove. In Mitchell's tudy, if the valves 
that failed because of infective endocarditis are dis- 
counted, the potential temporal window during which it is 
possible that immunologically mediated injury could have 
occurred undetected would be between 9 days and 6 
months. It is interesting that the valves in Kawauchi's 
study were examined 8 to 27 days after transplantation. 
This period almost fits into the aforementioned window of 
time. In our study, 2 mononuclear cell infiltrates were 
found in five infant cryopreserved homograft valves ex- 
planted after 6.5 to 31 weeks. It may be that this interme- 
diate implant interval represents he peak time for cellular 
rejection of homograft valves, especially in the younger 
pediatric population. 
We recently studied in detail nine homograft valves that 
were explanted from two children and seven adults whose 
ages ranged from 4 to 61 years. The time from valve 
insertion to removal in these patients ranged from 8 
months to 23 years. In contrast to the homograft valves in 
infants, infiltration by mononuclear cells was not ob- 
served. We noted moderate to marked intimal hyperplasia 
(composed of spindle cells positive for smooth muscle 
actin) in seven of the nine non-infant homografts. The 
intimal proliferation was very similar to the intima in graft 
vascular disease in solid organ transplants. Assuming that 
graft vascular disease is a form of rejection, the hyperplas- 
tic intima in these allografts would then represent ongoing 
rejection. We continue to believe that allograft valves in 
any age group arc not immunologically privileged. 
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Reply to the Editor." 
We read with interest he letter written by Kawauchi 
and associates 1 in response to our article concerning the 
pathology of explanted cryopreserved allograft heart 
valves versus aortic valves from orthotopic heart trans- 
plants. 2In a primate heterotopic heart transplant model, 
Kawauchi and colleagues have observed mononuclear 
inflammatory cells in association with the allograft aortic 
valve and have interpreted this to represent cell-mediated 
"rejection." Since they observe that the extent of inflam- 
matory infiltrate in the valves is lower than that seen 
within the myocardium proper, the authors also infer that 
the rejection of valves is weaker than that of the myocar- 
dium. As in the recent paper by Rajani and colleagues, 3 
the criteria that permit he presence of mononuclear cell 
infiltrates in valves to be interpreted as immunologically 
specific rejection are not stated. Moreover, there is no 
evidence that valve degeneration or dysfunction can be 
attributed to the inflammatory cells. Nevertheless, on the 
basis of these findings, as well as those reported previously 
in rat allograft valve experiments, < 5Kawauchi and asso- 
ciates 1suggest that "small-dose immunosuppression may 
arrest homograft degeneration." 
We believe that it is extremely important to respond to 
the lcttcr and to clearly reiterate two points that we made 
in our original article: (1) Tissue immunogenicity s not 
equivalent to immunologically mediated ysfunction. (2) 
Although inflammatory cell infiltrates are characteristi- 
cally associated with rejection, the presence of such cells 
does not necessarily denote a rejection pathogenesis. 
As regards the first point, allograft valves clearly may 
induce a detectable humoral and/or cellular allogencic 
response. 4-8 Indeed, it would be unusual if tissue express- 
ing foreign histocompatibility antigens did not elicit a 
detectable r sponse. However, there is not evidence that 
the observed loss of cellularity and architectural degener- 
ation of cryopreserved allograft valves can be attributed to 
such immunologic responses. Indeed, some sort of immu- 
nologic variant of Koch's postulates* should be satisfied 
before one concludes that immune destruction is the basis 
for valve failure. Essentially, it is first necessary to dem- 
onstrate that immunologically specific elements (antibod- 
ies or cells) are associated with failing valves; by the 
judicious use of isografts, an important corollary is that 
antibodies and cells found on valves are not nonspecifi- 
cally present because of surgical manipulation oraberrant 
flow conditions. The second step would be to use antibod- 
ies or cells from animals that have dysfunctional trans- 
planted valves and cause valve degeneration by transfer 
*To firmly establish that a specific bacterium isresponsible for a 
specific human disease, Robert Koch in the late nineteenth 
century proposed a set of objective criteria. These Koch's 
Postulates tate that the suspected bacterium should be 
routinely recovered from the pathologic lesions of the human 
host; in a pure form, these bacteria should cause the patho- 
logic lesions when inoculated into an animal host; and, tile 
bacterium should then be recoverable from the pathologic 
lesions in the animal. 
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into an appropriate second host (i.e., haplotype-matched 
to the original valve donor). Finally, the adoptively trans- 
ferred cells or antibodies should be recoverable from the 
failed valve in the second host. 
Animal models, such as that described by Kawauchi and 
colleagues, provide an excellent way to satisfy such pos- 
tulates. However, the appropriate xperiments have thus 
far not been done. In fact, in the animal and human 
studies cited, z' 4-8 workers have only demonstrated that 
allograft valves are immunogenic and that immunosup- 
pressants (e.g., cyclosporine [INN: ciclosporin]) may mod- 
ulate the ability to generate an immunologic response. 4 In 
our opinion there exists no evidence that valve destruction 
or loss of function is mediated by immune elements, or 
even that blockage of immune mechanisms by immuno- 
suppression prevents that outcome. 
The results of our examination of explanted cryopre- 
served allografts days to years after implantation 2 suggest 
that factors related to harvesting, handling, ischemic time, 
freezing, and thawing are most responsible for the loss of 
cellular viability. The absence of neutrophilic and/or in- 
creased mononuclear cell infiltrates (above the resident 
population in valves) in explanted cryopreserved valves, 
even at time points where clear-cut architectural changes and 
loss of celhtlar staining are occurring, leads to the conclu- 
sion that immunologic phenomena cannot be causally 
implicated in most allograft degeneration. Moreover, even 
in heart transplant patients where immunologic phenom- 
ena caused allograft failure, or where patients had multi- 
pie episodes of parenchymal rejection, evidence of immu- 
nologic injury to the valves is not seen (i.e., no valvular 
scarring or loss of cellularity). These results in orthotopic 
heart transplants uggest hat allogeneic valves may be 
relatively resistant to immune injury, perhaps owing to a 
combination of high flow, the normal lack of valvular 
microvasculature, low alloantigen expression, and/or 
lower expression of relevant adhesion or co-stimulator 
molecules. 2 In this regard, the observation by Kawauchi 
and associates ~ concerning lower apparent antigenicity of 
valves versus myocardium is intriguing, although a con- 
trolled comparison of the relative alloresponse (e.g., 
mixed lymphocyte culture) to valves vcrsus myocardium 
was not done. 
The second point above, that mononuclear cells do not 
equate to rejection, is particularly germane in regard to 
the conclusions reached by Kawauchi and colleagues] 
First, it is not possible to unequivocally conclude that the 
subendothelial valvular infiltrate is above background 
levels. No indication is given for the number of intrinsic 
resident mononuclear cells in the macaque monkey 
valves; our study found that normal human valves have a 
low level, diffuse population of macrophages and T cells 
present as normal cellular constituents. 2 Second, the 
composition of the mononuclear cells present has not 
been characterized; they may well be predominantly mac- 
rophages and not lymphocytes. Indeed, the single illustra- 
tion provided appears most like an organizing thrombus, 
which would be expected to have a large population of 
macrophages even in the absence of a specific immune 
response. Third, the fact that the model used by Kawa- 
uchi's group involves heterotopic cardiac atlografts (with 
recipient abdominal aortic anastomosis to donor ascend- 
ing aorta) means the vascular stasis and thrombosis both 
above and below the valve may be significant confounding 
factors. Obviously, in orthotopic transplantation, normal 
high flow across the valve will minimize the ability of cells 
and/or antibodies to adhere; in heterotopic transplanta- 
tion, substantial stasis, as well as the presence of organiz- 
ing thrombus, may allow an artifactually high accumula- 
tion of thcse immune elements. In this regard, analyzing 
the pulmonic valves from these orthotopic transplants 
(which will have more normal flow) may minimize the 
confounding variable of thrombosis. Finally, even in this 
heterotopic model, no evidence is presented to suggest 
that the mononuclear inflammatory cells are causing 
functional valve degeneration r that immunosuppression 
might be efficacious in modulating the inflammatory re- 
sponse. 
Consequently, although the findings of Kawauchi and 
coworkers are interesting, the model is incompletely char- 
acterized. Moreover, we believe that it is extremely pre- 
mature to advocate the use of immunosuppression (itself 
associated with widely known and substantial morbidity) 
to prevent valvular degeneration i cryopreserved allo- 
grafts, a process that appears to be a consequence of 
ischemia, freezing, and thawing, and for which we find no 
substantive evidence implicating an immune pathogenesis. 
R. N. Mitchell, MD, PhD 
F. J. Schoen, MD, PhD 
Department of Pathology 
Brigham and Women's Hospital 
75 Francis St. 
Boston, MA 02115 
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